BRCA-deficient Mouse Mammary Tumor Organoids to Study Cancer-drug Resistance

Overview

Journal Nat Methods

Specialties Biomedical Engineering
Pathology

Date 2017 Dec 20

PMID 29256493

Citations 84

Authors

Alexandra A Duarte

Ewa Gogola

Norman Sachs

Marco Barazas

Stefano Annunziato

Julian R de Ruiter

Arno Velds

Sohvi Blatter

Julia M Houthuijzen

Marieke van de Ven

Hans Clevers

Piet Borst

Jos Jonkers

Sven Rottenberg

Affiliations

Soon will be listed here.

Abstract

Poly(ADP-ribose) polymerase inhibition (PARPi) is a promising new therapeutic approach for the treatment of cancers that show homologous recombination deficiency (HRD). Despite the success of PARPi in targeting HRD in tumors that lack the tumor suppressor function of BRCA1 or BRCA2, drug resistance poses a major obstacle. We developed three-dimensional cancer organoids derived from genetically engineered mouse models (GEMMs) for BRCA1- and BRCA2-deficient cancers. Unlike conventional cell lines or mammospheres, organoid cultures can be efficiently derived and rapidly expanded in vitro. Orthotopically transplanted organoids give rise to mammary tumors that recapitulate the epithelial morphology and preserve the drug response of the original tumor. Notably, GEMM-tumor-derived organoids can be easily genetically modified, making them a powerful tool for genetic studies of tumor biology and drug resistance.

Citing Articles

Individualized Pooled CRISPR/Cas9 Screenings Identify CDK2 as a Druggable Vulnerability in a Canine Mammary Carcinoma Patient.

Inglebert M, Dettwiler M, He C, Markkanen E, Opitz L, Naguleswaran A Vet Sci. 2025; 12(2).

PMID: 40005944 PMC: 11861728. DOI: 10.3390/vetsci12020183.

PTEN loss drives p53 LOH and immune evasion in a novel urothelial organoid model harboring p53 missense mutations.

Hamada A, Kita Y, Sakatani T, Nakamura K, Takada H, Ikeuchi R Oncogene. 2025; .

PMID: 39987272 DOI: 10.1038/s41388-025-03311-5.

Docetaxel response in BRCA1,p53-deficient mammary tumor cells is affected by Huntingtin and BAP1.

Gonzalez-Fernandez M, Perry C, Gerhards N, Francica P, Rottenberg S Proc Natl Acad Sci U S A. 2024; 121(52):e2402849121.

PMID: 39705313 PMC: 11670238. DOI: 10.1073/pnas.2402849121.

The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy.

Bornes L, van Winden L, Geurts V, de Bruijn B, Azarang L, Lanfermeijer M Nature. 2024; 637(8044):195-204.

PMID: 39633046 PMC: 11666466. DOI: 10.1038/s41586-024-08276-1.

Application and prospect of organoid technology in breast cancer.

Huang S, Mei Z, Wan A, Zhao M, Qi X Front Immunol. 2024; 15:1413858.

PMID: 39253075 PMC: 11381393. DOI: 10.3389/fimmu.2024.1413858.

References

Brinkman E, Chen T, Amendola M, van Steensel B . Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014; 42(22):e168. PMC: 4267669. DOI: 10.1093/nar/gku936. View

Sato T, Vries R, Snippert H, van de Wetering M, Barker N, Stange D . Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009; 459(7244):262-5. DOI: 10.1038/nature07935. View

Duarte A, Gogola E, Sachs N, Barazas M, Annunziato S, de Ruiter J . BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance. Nat Methods. 2017; 15(2):134-140. DOI: 10.1038/nmeth.4535. View

Rottenberg S, Nygren A, Pajic M, van Leeuwen F, van der Heijden I, van de Wetering K . Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A. 2007; 104(29):12117-22. PMC: 1914039. DOI: 10.1073/pnas.0702955104. View

Ang J, Gourley C, Powell C, High H, Shapira-Frommer R, Castonguay V . Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res. 2013; 19(19):5485-93. DOI: 10.1158/1078-0432.CCR-13-1262. View

Grabinger T, Luks L, Kostadinova F, Zimberlin C, Medema J, Leist M . Ex vivo culture of intestinal crypt organoids as a model system for assessing cell death induction in intestinal epithelial cells and enteropathy. Cell Death Dis. 2014; 5:e1228. PMC: 4047863. DOI: 10.1038/cddis.2014.183. View

. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012; 489(7414):57-74. PMC: 3439153. DOI: 10.1038/nature11247. View

Drost J, van Jaarsveld R, Ponsioen B, Zimberlin C, van Boxtel R, Buijs A . Sequential cancer mutations in cultured human intestinal stem cells. Nature. 2015; 521(7550):43-7. DOI: 10.1038/nature14415. View

Wang D, Mou H, Li S, Li Y, Hough S, Tran K . Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. Hum Gene Ther. 2015; 26(7):432-42. PMC: 4509492. DOI: 10.1089/hum.2015.087. View

10.

Koo B, Stange D, Sato T, Karthaus W, Farin H, Huch M . Controlled gene expression in primary Lgr5 organoid cultures. Nat Methods. 2011; 9(1):81-3. DOI: 10.1038/nmeth.1802. View

11.

Freedman B, Brooks C, Lam A, Fu H, Morizane R, Agrawal V . Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids. Nat Commun. 2015; 6:8715. PMC: 4620584. DOI: 10.1038/ncomms9715. View

12.

Bunting S, Callen E, Wong N, Chen H, Polato F, Gunn A . 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010; 141(2):243-54. PMC: 2857570. DOI: 10.1016/j.cell.2010.03.012. View

13.

Xu G, Chapman J, Brandsma I, Yuan J, Mistrik M, Bouwman P . REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature. 2015; 521(7553):541-544. PMC: 4671316. DOI: 10.1038/nature14328. View

14.

Tkac J, Xu G, Adhikary H, Young J, Gallo D, Escribano-Diaz C . HELB Is a Feedback Inhibitor of DNA End Resection. Mol Cell. 2016; 61(3):405-418. DOI: 10.1016/j.molcel.2015.12.013. View

15.

Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte A, Lee J . Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016; 535(7612):382-7. PMC: 4959813. DOI: 10.1038/nature18325. View

16.

Bruna A, Rueda O, Greenwood W, Batra A, Callari M, Batra R . A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell. 2016; 167(1):260-274.e22. PMC: 5037319. DOI: 10.1016/j.cell.2016.08.041. View

17.

Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A . Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet. 2001; 29(4):418-25. DOI: 10.1038/ng747. View

18.

Ashworth A . A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008; 26(22):3785-90. DOI: 10.1200/JCO.2008.16.0812. View

19.

Kuilman T, Velds A, Kemper K, Ranzani M, Bombardelli L, Hoogstraat M . CopywriteR: DNA copy number detection from off-target sequence data. Genome Biol. 2015; 16:49. PMC: 4396974. DOI: 10.1186/s13059-015-0617-1. View

20.

Patch A, Christie E, Etemadmoghadam D, Garsed D, George J, Fereday S . Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015; 521(7553):489-94. DOI: 10.1038/nature14410. View